Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death

Cancer Research

Volumn 59, Issue 15, 1999, Pages 3565-3569

  Sané, Alain Théophile ^a   Bertrand, Richard ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTIC ACID FLUOROMETHYLKETONE; CAMPTOTHECIN; CASPASE; CASPASE INHIBITOR; CYCLIN DEPENDENT KINASE; DNA TOPOISOMERASE INHIBITOR; TRIPEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; DNA STRAND BREAKAGE; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA; PRIORITY JOURNAL;

AMINO ACID CHLOROMETHYL KETONES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CASPASES; CELL CYCLE PROTEINS; DNA DAMAGE; DNA FRAGMENTATION; DNA REPAIR; DNA REPLICATION; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; ENZYME ACTIVATION; ENZYME INHIBITORS; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NECROSIS; NEOPLASM PROTEINS; U937 CELLS;

EID: 0033178946     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Gupta, M., Fujimori, A., and Pommier, Y. Eukaryotic DNA topoisomerase I. Biochim. Biophys. Acta, 1202: 1-14, 1995.
2. Pommier, Y. DNA Topoisomerase II inhibitors. In: B. A. Teicher (ed.), Cancer Therapeutics: Experimental and Clinical Agents, pp. 153-174. Totowa, New Jersey: Humana Press Inc, 1997.
3. Kaufmann, S. H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res., 49: 5870-5878, 1989.
4. Barry, M. A., Behnke, C. A., and Eastman, A., Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol., 40: 2353-2362, 1990.
5. Bertrand, R., Sarang, M., Jenkin, J., Kerrigan, D., and Pommier, Y. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. Cancer Res., 51: 6280-6285, 1991.
6. Del Bino, G., and Darzynkiewicz, Z. Camptothecin, Teniposide, or 4′-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S-phase HL-60 cells. Cancer Res., 51: 1165-1169, 1991.
7. Walker, P. R., Smith, C., Youdale, T., Leblanc, J., Whitfield, J. F., and Sikorska, M. Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res., 51: 1078-1085, 1991.
8. Hickman, J. A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev., 11: 121-139, 1992.
9. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997.
10. Dubrez, L., Savoy, I., Hamman, A., and Solary, E. Pivotal role of a DEVD-sensitive step in etoposide-induced and Fas-mediated apoptotic pathways. EMBO J., 15: 5504-5512, 1996.
11. Martins, L. M., Kottke, T., Mesner, P. W., Basi, G. S., Sinha, S., Frigon, N., Tatar, E., Tung, J. S., Bryant, K., Takahashi, A., Svingen, P. A., Madden, B. J., McCormick, D. J., Earnshaw, W. C., and Kaufmann, S. H. Activation of multiple interleukin-1-β converting enzyme homologues in cytosol and nuclei of HI-60 cells during etoposide-induced apoptosis. J. Biol. Chem., 272: 7421-7430, 1997.
12. Sané, A. T., and Bertrand, R. Distinct steps in DNA fragmentation pathway during camptothecin-induced apoptosis involved caspase-, benzyloxycarbonyl- and N-tosyl-L-phenylalanylchloromethyl ketone-sensitive activities. Cancer Res., 58: 3066-3072, 1998.
13. Alnemri, E. S. Mammalian cell death proteases: a family of highly conserved aspartate specific cysteine proteases. J. Cell Biochem., 64: 33-42, 1997.
14. Cryns, V., and Yuan, J. Y. Proteases to die for. Genes Dev., 12: 1551-1570, 1998.
15. Schmitt, E., Sane, A. T., and Bertrand, R. Activation and role of caspases in chemotherapy-induced apoptosis. Drug Resistance Updates, 2: 21-29, 1999.
16. Kuida, K., Haydar, T. F., Kuan, C. Y., Gu, Y., Taya, C., Karasuyama, H., Su, M. S. S., Rakic, P., and Flavell, R. A. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell, 94: 325-337, 1998.
17. Yoshida, H., Kong, Y. Y., Yoshida, R., Elia, A. J., Hakera, A., Hakem, R., Penninger, J. M., and Mak, T. W. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell, 94: 739-750, 1998.
18. Liu, X. S., Zou, H., Slaughter, C., and Wang, X. D. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell, 89: 175-184, 1997.
19. Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., and Nagata, S. A caspase-activated DNAse that degrades DNA during apoptosis, and its inhibitor ICAD. Nature (Lond.), 391: 43-50, 1998.
20. Halenbeck, R., Macdonald, H., Roulston, A., Chen, T. T., Conroy, L., and Williams, L. T. CPAN, a human nuclease regulated by the caspase-sensitive inhibitor DFF45. Curr. Biol., 8: 537-540, 1998.
21. Kerr, J. F., Wyllie, A. H., and Currie, A. R. Apoptosis, a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer, 26: 239-257, 1972.
22. L modulates apoptosis induced by anticancer drugs and delays DEVDase and DNA fragmentation-promoting activities. Exp. Cell Res., 240: 107-121, 1998.
23. Bertrand, R., O'Connor, P., Kerrigan, D., and Pommier, Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human carcinoma, HT-29 cells. Eur. J. Cancer, 28A: 743-748, 1992.
24. Thornberry, N. A., Ranon, T. A., Pieterson, E. P., Rasper, D. M., Timkey, T., Garciacalvo, M., Houtzager, V. M., Nordstrom, P. A., Roy, S., Vaillancourt, J. P., Chapman, K. T., and Nicholson, D. W. A combinatorial approach defines specificities of members of the caspase family and granzyme B: functional relationships established for key mediators of apoptosis. J. Biol. Chem., 272: 17907-17911, 1997.
25. Bicknell, G. R., and Cohen, G. M. Cleavage of DNA to large kilobase pair fragments occurs in some forms of necrosis as well as apoptosis. Biochem. Biophys. Res. Comm., 207: 40-47, 1995.
26. Hirsch, T., Marchetti, P., Susin, S. A., Dallaporta, B., Zamzami, N., Marzo, I., Geuskens, M., and Kroemer, G. The apoptosis-necrosis paradox: apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene, 15: 1573-1581, 1997.
27. Lemaire, C., Andreau, K., Souvannavong, V., and Adam, A. Inhibition of caspase activity induces a switch from apoptosis to necrosis. FEBS Lett., 425: 266-270, 1998.
28. Kaufmann, S. H. Cell death induced by topoisomerase-targeted drugs - more questions than answers. Biochim. Biophys. Acta, 1400: 195-211, 1998.
29. Thomas, A., Elrouby, S., Reed, J. C., Krajewski, S., Silber, R., Potmesil, M., and Newcomb, E. W. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and Bcl-2/Bax proteins in drug resistance. Oncogene, 12: 1055-1062, 1996.
30. Waldman, T., Lengauer, C., Kinzler, K. W., and Vogelstein, B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature (Lond.), 381: 713-716, 1996.
31. Gupta, M., Fan, S. J., Zhan, Q. M., Kohn, K. W., O'Connor, P. M., and Pommier, Y. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin. Cancer Res., 3: 1653-1660, 1997.
32. Shi, L., Nishioka, W. K., Th'ng, J., Bradbury, E. M., Litchfield, D. W., and Greenberg, A. H. Premature p34cdc2 activation required for apoptosis. Science (Washington DC), 263: 1143-1145, 1994.
33. Pandey, S., and Wang, E. Cells en route to apoptosis are characterized by the upregulation of c-fos, c-myc, c-jun, cdc2, and RB phosphorylation, resembling events of early cell-cycle traverse. J. Cell. Biochem., 58: 135-150, 1995.
34. Shimizu, T., O'Connor, P. M., Kohn, K. W., and Pommier, Y. Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res., 55: 228-231, 1995,
35. cdc2 kinase for apoptosis mediated by the Fas/Apo-1 receptor and interleukin 1-β-converting enzyme-related proteases. Cancer Res., 56: 4551-4555, 1996.
36. Martin, S. I., McGahon, A. J., Nishioka, W. K., LaFace, D., Guo, X., Th'ng, J., Bradbury, E. M., and Green, D. R. p34cdc2 and apoptosis. Science (Washington DC), 209: 106-107, 1995.
37. O'Connor, P. M., Nieves-Neira, W., Kerrigan, D., Bertrand, R., Goldman, J., Kohn, K. W., and Pommier, Y., S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Commun., 3: 233-240, 1991.
38. Kasten, M. M., and Giordano, A. pRB and the CDKs in apoptosis and the cell cycle. Cell Death Differ., 5: 132-140, 1998.